Abstract
Up to 40% of donor-recipient pairs in SCT have some degree of ABO incompatibility, which may cause severe complications. The aim of this study was to describe available options and survey current practices by means of a questionnaire circulated within the EBMT Pediatric Diseases Working Party investigators. Major ABO incompatibility (donor’s RBCs have antigens missing on the recipient’s cell surface, towards which the recipient has circulating isohemagglutinins) requires most frequently an intervention in case of bone marrow grafts, as immediate or delayed hemolysis, delayed erythropoiesis and pure red cell aplasia may occur. RBC depletion from the graft (82%), recipient plasma-exchange (14%) were the most common practices, according to the survey. Graft manipulation is rarely needed in mobilized peripheral blood grafts. In case of minor incompatible grafts (donor has isohemagglutinins directed against recipient RBC antigens), isohemagglutinin depletion from the graft by plasma reduction/centrifugation may be considered, but acute tolerability of minor incompatible grafts is rarely an issue. According to the survey, minor ABO incompatibility was either managed by means of plasma removal from the graft, especially when isohemagglutinin titer was above a certain threshold, or led to no intervention at all (41%). Advantages and disadvantages of each method are discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
04 August 2020
A Correction to this paper has been published: https://doi.org/10.1038/s41409-020-01012-z
References
Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1152–8. https://doi.org/10.1016/j.bbmt.2013.03.018.
Staley EM, Schwartz J, Pham HP. An update on ABO incompatible hematopoietic progenitor cell transplantation. Transfus Apher Sci. 2016;54:337–44. https://doi.org/10.1016/j.transci.2016.05.010.
Lapierre V, Kuentz M, Tiberghien P. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice. Société Française de Greffe de Moelle. Bone Marrow Transpl. 2000;25:507–12.
Raimondi R, Soli M, Lamparelli T, Bacigalupo A, Arcese W, Belloni M. Gruppo Italiano Trapianto di Midollo Osseo et al. ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature. Bone Marrow Transpl. 2004;34:321–9.
Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011;46:1167–85. https://doi.org/10.1038/bmt.2011.135
Sorg N, Poppe C, Bunos M, Wingenfeld E, Hümmer C, Krämer A, et al. Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies. Transfusion 2015;55:1275–82. https://doi.org/10.1111/trf.13001.
Kim-Wanner SZ, Bug G, Steinmann J, Ajib S, Sorg N, Poppe C, et al. Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia. BMC, J Transl Med. 2017;15:1 https://doi.org/10.1186/s12967-017-1277-6
Bonig H, Bug G. RBC depletion from a PBSC graft. Bone Marrow Transplant 2017;52:1078–9. https://doi.org/10.1038/bmt.2017.72.
Sheppard D, Tay J, Bryant A, McDiarmid S, Huebsch L, Tokessy M, et al. Major ABO-incompatible BMT: isohemagglutinin reduction with plasma exchange is safe and avoids graft manipulation. Bone Marrow Transpl. 2013;48:953–7. https://doi.org/10.1038/bmt.2012.264.
Stussi G, Halter J, Bucheli E, Valli PV, Seebach L, Gmür J, et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica. 2009;94:239–48. https://doi.org/10.3324/haematol.13356.
Scholl S, Klink A, Mügge LO, Schilling K, Höffken K, Sayer HG. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Transfusion. 2005;45:1676–83.
Nussbaumer W, Schwaighofer H, Gratwohl A, Kilga S, Schönitzer D, Nachbaur D, et al. Transfusion of donor-type red cells as a single preparative treatment for bone marrow transplants with major ABO incompatibility. Transfusion. 1995;35:592–5.
Curley C, Pillai E, Mudie K, Western R, Hutchins C, Durrant S, et al. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange. Transfusion. 2012;52:291–7. https://doi.org/10.1111/j.1537-2995.2011.03295.x.
Besides the Authors, the following Investigators (in alphabetical order) contributed to the EBMT PD WP survey mentioned in this manuscript:
Bella Bielorai20,21, Simone Cesaro22, Tamara Diesch23, Koji Kato24, Sergio Gomez25, Karin Mellgren26, Julia Palma27, Claudia Rossig28, Martin Sauer29, Petr Sedlacek30, Peter Shaw31, Kirk Schultz32, Jerry Stein33, Güngör Tayfun34, Dominik Turkiewicz35, Jacekz Wachowiak36.
20Department of Pediatric Hematology-Oncology, The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Ramat-Gan, Israel. 21Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 22Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. 23University Children’s Hospital Basel, Division of Pediatric Oncology/Hematology, Basel, Switzerland. 24Haematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan. 25Stem Cell Transplantation Unit, Hospital de Niños Sor María Ludovica, La Plata, Argentina. 26Institution for Clinical Sciences, Department of Paediatrics, Queen Silvia Children’s Hospital, Gothenburg, Sweden. 27Stem Cell Transplant Unit, Hospital Luis Calvo Mackenna, Santiago, Chile. 28Department of Pediatric Hematology and Oncology, University Children’s Hospital Muenster, Muenster, Germany. 29Department of Pediatric Hematology and Oncology, University Hospital, Hannover Medical School, Hannover, Germany. 30Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic. 31The Children’s Hospital at Westmead, Oncology Unit, Westmead, Sydney, NSW, Australia. 32Department of Pediatrics, British Columbia Children’s Hospital, British Columbia, Canada. 33Pediatric Hematology Oncology, Schneider Children’s Medical Center of Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 34Division of Stem Cell Transplantation, Department of Pediatrics, University Children’s Hospital, Zürich, Switzerland. 35Children’s Hospital, Skåne University Hospital, Lund, Sweden. 36Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland.
Author information
Authors and Affiliations
Consortia
Contributions
AB and HB wrote the manuscript, AJ, JHD, RM gave major contributions, PB initiated the Supportive Task Force within the EBMT Pediatric Diseases Working Party and AW coordinated it; all the authors contributed to the survey reported in the manuscript; all authors reviewed the manuscript and approved its final version.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Members of the EBMT Pediatric Diseases Working Party are listed before references.
Rights and permissions
About this article
Cite this article
Balduzzi, A., Bönig, H., Jarisch, A. et al. ABO incompatibile graft management in pediatric transplantation. Bone Marrow Transplant 56, 84–90 (2021). https://doi.org/10.1038/s41409-020-0981-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0981-7